Gene therapy and gene editing get all the glory, but investors shouldn't overlook an emerging group of tools.

The share price dipped below $1 -- into penny stock territory -- but analysts are optimistic they'll recover.

Barclays made a list of 35 stocks with overweight ratings that it expects to benefit from strong earnings next year.

Sarepta's trial supports its drug's 'potentially differentiated profile' to treat Duchenne muscular dystrophy, the company said. The stock is higher.

Stocks moving in premarket trading Friday include Boeing, Micron, Pfizer, Sarepta and Moderna.

Tesla CEO Musk discusses succession plans and Twitter with shareholders.

The company has made clear what it plans on the Las Vegas Strip, but it has a fast-approaching deadline.

Long-delayed futuristic looking electric vehicle will be in production by the middle of 2023